Although the role of EGFR in the pathophysiology of ALS has not been fully clarified, the promising results obtained from the abovementioned and other EGFR inhibitors (e.g., PKI166, BMS690514, canertinib, gefitinib, PD153035) make them attractive candidates for further preclinical studies (Fig. 5). Here, EGFR is linked to amyotrophic lateral sclerosis.